Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
| Autor: | Satoko Kojima, Yukio Naya, Masahiko Inahara, Kanya Kaga, Hiroshi Masuda, Kazuhiro Araki, Makoto Takano |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Hypophosphatemia Urology 030209 endocrinology & metabolism lcsh:RC870-923 urologic and male genital diseases Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Medicine 030212 general & internal medicine Bone pain business.industry lcsh:Diseases of the genitourinary system. Urology medicine.disease Pancytopenia Surgery Prostate-specific antigen medicine.anatomical_structure Denosumab Oncology Hemodialysis medicine.symptom business medicine.drug |
| Zdroj: | Urology Case Reports, Vol 13, Iss C, Pp 63-65 (2017) Urology Case Reports |
| ISSN: | 2214-4420 |
| Popis: | In a 68-year-old man on maintenance hemodialysis (HD), severe anemia was detected. Bone marrow biopsy was performed for investigation of pancytopenia and pathological examination revealed adenocarcinoma of the prostate. Prostate specific antigen (PSA) was 574 ng/mL. After androgen deprivation therapy was initiated, PSA decreased to 13.7 ng/mL. But subsequent elevation of PSA and pain due to bone metastases were recognized. Denosumab (120 mg) was administered. Although improvement of bone pain was observed, severe hypocalcemia occurred. Severe hypophosphatemia was subsequently detected. When we use denosumab in dialysis patients with advanced cancer, we should be careful of hypophosphatemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|